Cooperate with the Molecular Partners DARPin platform and Novartis’ world-class capabilities in radioligand therapy to explore the potential of new cancer targeted therapies
Novartis will pay an upfront payment of US$20 million, commercial royalties not to exceed double digits, and milestone payments.
Zurich-Schlieelen, Switzerland and Concord, Massachusetts, December 14, 2021 (Global News Agency)-Special announcement under Article 2. 53 LR:
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) is a clinical-stage biotechnology company that is developing a new customized protein drug called DARPin therapy. It announced today that it has cooperated with Novartis in the form of a license agreement to develop, manufacture and Commercial DARPin-conjugated radioligand therapy (DARPin-RLTs). This collaboration will combine Molecular Partners' industry-leading ability to quickly generate high-affinity DARPins and Novartis' RLT capabilities and expertise.
By using the power of radioactive atoms and applying it to cancer through targeted radioligand therapy, RLT has the potential to deliver molecular targeted radiation to tumor cells anywhere in the body. Under the terms of the agreement, Molecular Partners will work with Novartis to discover DARPin-RLT for specific tumor-associated antigens. DARPins have great potential to achieve robust, tumor-specific delivery of radioligands because of their small size, allowing greater tumor penetration, and high specificity and affinity.
"We are very pleased to announce this new collaboration with Novartis. Over the past few years, the NIBR team has established itself as a world leader in the RLT field, and working with them on this project is an easy choice," Molecular Partners CEO Patrick Amstutz (Patrick Amstutz) said. "Although DARPins can be designed to perform any number of biological tasks, here we highlight some of their innate characteristics, including small size and high specificity and affinity, which may provide advantages for RLTs that usually require highly specific delivery vectors. ."
Jay Bradner, director of the Novartis Institute of Biomedical Research, said: “Radioligand therapy is a transformative platform for delivering radiation to target cells, and DARPins are a unique way to target tumors. "The combination of these two technologies aims to enable us to directly target the radioligand to tumor cells in any part of the body, with the goal of improving and prolonging the lives of patients. "
According to the agreement, the two parties will cooperate in the discovery and optimization of therapeutic candidate drugs. Novartis will be responsible for all clinical development and commercialization activities. Novartis will pay Molecular Partners US$20 million in advance, total potential development, regulatory and commercialization milestone payments of up to US$560 million, as well as low double-digit royalties.
About Molecular Partners AG Molecular Partners AG is a clinical-stage biotechnology company that develops DARPin therapy, a new type of customized protein drug designed to solve challenges that cannot be solved by current models. The company has established partnerships with leading pharmaceutical companies to advance DARPin treatments in the fields of ophthalmology, oncology and infectious diseases, and has compounds in various stages of clinical and preclinical development in multiple therapeutic areas. www.molecularpartners.com; find us on Twitter-@MolecularPrtnrs' warning about forward-looking statements The definition in the Litigation Reform Act (as amended) includes, but is not limited to, implied and express statements about the clinical development of Molecular Partners’ current or future product candidates, including expectations of the timing of clinical trials or the potential therapeutic and clinical benefits of Molecular Partners’ product candidates, Viral mutations and variants of SARS-CoV-2 including the future efficacy of ensovibep. These statements may be identified by words such as "expect", "may", "plan", "potential", "will" and similar expressions and are based on the current beliefs and expectations of Molecular Partners AG. These statements involve risks and uncertainties, which may cause actual results to differ materially from the results reflected in such statements. Some key factors that may cause actual results to differ from our expectations include our ongoing and planned clinical trials and preclinical studies, including the timing of such trials and studies; the results of preclinical studies and clinical trials may not be predictive of future clinical trials. The risk of future results related to the experiment; our reliance on third-party partners and collaborators, we may not be able to fully control; our plan to develop and potentially commercialize our product candidates; we obtain and maintain the results of our product candidates The timing of regulatory approvals and our capabilities; the scope of clinical trials that our candidate products may require; the clinical utility and capabilities of our candidate products that are recognized by the market; the potential impact of the COVID-19 pandemic on our operations or clinical trials; Testing may not be able to confirm the risk of ensovibep's efficacy in reproducing all mutated viruses (complete Omicron pseudo-variants) at the same time; the planning and development of any new indications for our product candidates; our commercialization, marketing and manufacturing capabilities And strategy; our intellectual property status; our ability to identify and license other product candidates; the risk factor section of the F-1 registration statement submitted by Molecular Partners to the U.S. Securities and Exchange Commission (SEC) on June 14, 2021, and Molecular Other risks and uncertainties described in other documents submitted by Partners to the SEC. These documents can be found on the Investor page of the Molecular Partners website http://www.molecularpartners.com. Any forward-looking statements are only issued on the date of this press release and are based on information available to Molecular Partners as of the date of this press release, and Molecular Partners does not undertake and does not intend to update any forward-looking statements-forward-looking statements, regardless of Is it due to new information, future events, or other reasons.
Molecular Partners AG (NASDAQ: MOLN) and Novartis (NYSE: NVS) have signed a license agreement to develop, manufacture and commercialize DARPin-conjugated radioligand therapy (DARPin- RLTs). According to the license agreement, Novartis will pay Molecular Partners US$20 million in advance. The total transaction amount also includes milestone payments of up to 560 million U.S. dollars and low double-digit percentage royalties. Novartis will be responsible for all clinical development and commercialization
Just two weeks ago, Tillman Gerngross, CEO of Adagio Therapeutics Inc., believed that his company's experimental antibody would "neutralize SARS-CoV-2 and all known variants." The new data shows that this is not the case.
As the coronavirus vaccine is about to be commercialized globally, it may take several months for Novavax (NASDAQ: NVAX) to sit down and watch the money roll in. In my opinion, Novavax will be in the middle of the decade. In three years, the company may launch three products on the market, but from now to then, it needs to do a lot of work in the clinic. Its coronavirus vaccine, currently called NVX-CoV2373, is likely to be the first product in its history to receive regulatory approval.
Pfizer’s stock price was raised from UBS’s neutral to buy. The company wrote that it expects sales of the antiviral drug Paxlovid to reach at least $14 billion next year, which is 40% higher than Wall Street’s expectations. UBS analyst Colin Bristow also raised his target price for the stock from $52 to $60 in a research report on Monday. Pfizer (stock code: PFE) shares rose 2.5% to $54.10. Bristol writes that Pfizer’s Covid franchises — Paxlovid and Cominarty, the company’s Covid-19 vaccine — have a peak sales potential of $50 billion in 2022.
After Merck's Covid pill, Monoprevir, is reviewed by an FDA consultant, will it be bought or sold? Is MRK stock now bought or sold?
Pfizer said that additional data confirmed the mid-term results. If the drug is taken within three days of the onset of symptoms, the risk of hospitalization or death can be reduced by 89%.
Author: Dr. David Bautz Nasdaq: TNXP Read the complete TNXP research report business update multiple research centers. These facilities will enable the company to better control early
Pfizer stated that the pill to treat COVID-19 may be approved at the end of the year or early 2022: “It changes the rules of the game”
Sigilon Therapeutics Inc. will lay off 40 employees, accounting for 38% of its total workforce, and reduce its work on drugs for rare blood diseases.
The giant pharmaceutical company Pfizer agreed earlier today to acquire Arena Pharmaceuticals for approximately US$6.7 billion.
No immune system is like another, so some people may not experience side effects at all, even if their bodies work equally hard.
Pfizer said on Tuesday that its experimental pill for the treatment of COVID-19 appears to be effective on the omicron variant. The company also said that the full results of its 2,250-person study confirmed the drug’s early promising results against the virus: when the drug is taken shortly after the initial symptoms of COVID-19, the drug will affect the total number of hospitalizations and deaths of high-risk adults. A reduction of about 89%. The company announced that, as predicted by many experts, separate laboratory tests have shown that the drug retains its effectiveness against omicron variants. Pfizer tested antiviral drugs against a man-made version of a key protein used by omicron to reproduce itself.
New jabs for the latest strains can be produced before March 2022
"The good news about this is that the data shows that approximately 89% of patients will not be hospitalized or die within the first few days of onset of symptoms, and now the complete final data set is just as good, or even better."
Oncotelic Therapeutics, Inc. ("Oncotelic" or "Company") (OTCQB: OTLC), a leading developer of TGF-β therapy in oncology and virology, today announced that the company's chief clinical officer...
Sanofi (NASDAQ: SNY) provided data from two Phase 3 studies of Fitusiran for the preventive treatment of hemophilia A or B (with or without inhibitors). The data is shared at the annual meeting of the American Society of Hematology (ASH). Fitusiran is an RNAi drug designed to silence genes that overproduce the protein responsible for coagulation inhibition. Fitusiran reduced the patient’s annualized bleeding rate (ARB) rate by 89%, which exceeded the control, proving that the prevention of bleeding events is a Monte Carlo
New Delhi (Reuters)-The CEO of the Serum Institute of India (SII) said on Tuesday that it plans to launch the Novavax COVID-19 vaccine for children in the country within six months, adding that the global vaccine supply exceeds that of many countries. Absorptive capacity. Adar Poonawalla said at a virtual conference organized by the Federation of Indian Industry that the world's largest vaccine manufacturer calls the Novavax vaccine Covovax, which has shown good results in trials with children three years of age and older.
Fearing that omicron variants of the virus may soon flood the UK, Covid vaccine stocks have soared.
Oklahoma Coronavirus information resources, including deaths, hospitalizations, vaccinations, and new cases.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or "Company") (TSX: EPRX), a clinical-stage biotechnology company with innovative drug delivery platform technology, today announced that it has submitted and obtained a preliminary short-form foundation The receipt and the shelf prospectus of the securities regulators in each province and territory of Canada.